Strong organic growth at Corilus and Fagron
Waregem (Belgium) / Rotterdam (the Netherlands)[1], 8 April 2011 – In the first quarter of 2011, the consolidated turnover of Arseus increased 15.0% to € 111.3 million. Organic growth was 3.2%.
The evolution of turnover[2] per division is as follows
x 1,000 euros Q1 2011 Q1 2010 Total growth Org. growth Fagron 51,323 38,633 +32.8% +8.2% Arseus Dental 39,315 38,423 +2.3% +0.1% Arseus Medical 12,502 12,632 -1.0% -6.5% Corilus 8,205 7,103 +15.5% +4.6% Total 111,345 96,791 +15.0% +3.2%
Ger van Jeveren, CEO of Arseus: ‘Arseus had a good start of 2011 with turnover growth of 15.0% and organic growth of 3.2%. All divisions of Arseus laid a solid foundation for growth by continuous investments in innovation and product development. This press release explains a number of these innovations.
In the first quarter, the integration of the Brazilian DEG and the Belgian Devroe, both acquired in December, was successfully completed. I am enthusiastic about the many benefits and possibilities that these acquisitions offer for our clients and our employees.
In 2011 Fagron wants to further strengthen its worldwide market leadership in the rapidly growing market for pharmaceutical compounding. Add-on acquisitions in existing markets are being considered for Arseus Dental, Arseus Medical and Corilus as suitable opportunities arise.
We look to the future with confidence and consequently confirm the expectations for 2011 that we announced earlier.’
[1] This press release was sent out by Arseus NV and Arseus BV.
[2] Unaudited management figures.
Please open the link below for the full press release: